Guerbet

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

Retrieved on: 
Monday, February 13, 2023
Radiology, Brain, NDA, Spine, Diagnosis, Tissue, Safety, Gadolinium, Head, MRI, Abdomen, Pelvis, Hospital, University, Neck, GBCA, Thorax, Relaxation, Proton, Hospital of the University of Pennsylvania, FDA, Magnetic resonance imaging, Neuroradiology, Central nervous system, Perelman School of Medicine at the University of Pennsylvania, Medical imaging, Guerbet

PRINCETON, N.J., Feb. 13, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022. This next generation GBCA from Guerbet, highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.1,4 Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs, addressing practitioners' concerns about gadolinium exposure.2,3 The first dosing took place at the Hospital of the University of Pennsylvania in Philadelphia, PA.

Key Points: 
  • Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs, addressing practitioners' concerns about gadolinium exposure.
  • 2,3
    PRINCETON, N.J., Feb. 13, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.
  • This milestone is the first of many for this novel new product, which has proven to be a promising step forward for the scientific and digital imaging community," said David Hale, Chief Executive Officer at Guerbet.
  • Elucirem is manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina.

Guerbet Releases First Production Batch of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

Retrieved on: 
Thursday, February 2, 2023
Acute kidney injury, Brain, Physician, NSF, Spine, Commercial, Tissue, MRI, Head, Abdomen, Food, Pelvis, Patient, Neck, GBCA, Diabetes, Thorax, Risk, Relaxation, Proton, Hypertension, Glomerular filtration rate, FDA, Magnetic resonance imaging, GFR, Central nervous system, Medical imaging, Pharmaceutical industry, Guerbet

PRINCETON, N.J., Feb. 2, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the first production batch has been manufactured and released for Elucirem™ (gadopiclenol) injection following FDA approval on September 21, 2022, after priority review.4  This next generation GBCA from Guerbet, highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.1,5

Key Points: 
  • "Releasing the first batch from our production facility in North Carolina is an important moment for everyone at Guerbet and we are proud to see the hard work and dedication come to fruition."
  • Elucirem is manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina and is now available for order.
  • Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
  • The risk for NSF appears highest among patients with:
    Screen patients for acute kidney injury and other conditions that may reduce renal function.

Guerbet: 2022 revenue

Retrieved on: 
Thursday, February 9, 2023
Software, Diagnosis, Medical imaging, MRI, Iodine, Intelligence, EBITDA, CER, Guerbet, Watson (computer), Therapy, Acceleration, Pharmaceutical industry

Annual revenue in Diagnostic Imaging was up 1.7% at current exchange rates and down -2.2% at CER.

Key Points: 
  • Annual revenue in Diagnostic Imaging was up 1.7% at current exchange rates and down -2.2% at CER.
  • X-ray activity declined -4.4% at CER in 2022 due to the lower revenue from Optiray®.
  • Confirmation of the 2022 profitability target, acceleration of activity in 2023
    For 2022, despite the revenue shortfall associated with the temporary drop in production in Raleigh, Guerbet confirmed its ability to generate an EBITDA margin of between 13% and 14%, excluding extraordinary costs from the optimization of the Group’s operating structure and changes in the sales model in China.
  • Its revenue growth target for this year is above 5% on a like-for-like basis and at constant exchange rates.

Guerbet: 2023 Strategic Priorities

Retrieved on: 
Monday, January 16, 2023
Prostate cancer, European Medicines Agency, Algorithm, Face, HSG, Hysterosalpingography, Liver, X-ray, Environment, Watson (computer), Microparticle, Research, Google Images, Lymphogram, IBM Watson Health, Intellectual property, Iodine, Growth, Lipiodol, Intelligence, Liver cancer, MRI, Investment, Acquisition, EMA, Risk management, Medical imaging, Guerbet, Mer (software distribution)

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.

Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

Retrieved on: 
Sunday, January 22, 2023
Annual report, International investment agreement, Depreciation, Algorithm, EBITDA, Research, SGL, Samsung Galaxy Note 10, Risk, R, Prospectus, Growth, Policy, Exercise, Radiology, Software as a service, AMF, Conseil, Intelligence, Security (finance), Cryptocurrency, Management, Bank, Holding company, Audit, Renewable energy, Guerbet, Offer

The financing provided to Intrasense through the Share Capital Increase will allow the Company to strengthen and accelerate the execution of its strategy in the coming years.

Key Points: 
  • The financing provided to Intrasense through the Share Capital Increase will allow the Company to strengthen and accelerate the execution of its strategy in the coming years.
  • This Share Capital Increase will provide Intrasense with a financing horizon of more than 48 months after the completion of the transaction.
  • The breakdown of the Company's share capital and voting rights before and after the Share Capital Increase is presented in Appendix 1 to this press release.
  • Following the completion of the Share Capital Increase, Guerbet plans to file a voluntary tender offer for the balance of the shares of Intrasense at a price of 0.44 euro per share and on the outstanding warrants.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

Retrieved on: 
Thursday, November 3, 2022
Research, RSNA, AI, Communication, GBT, BPI, ECR, Artificial intelligence, Mer (software distribution), Pancreatic cancer, Intelligence, Partnership, Euronext Paris, Prostate cancer, Program, Solution, Guerbet

Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.

Key Points: 
  • Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.
  • This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers.
  • The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of Artificial Intelligence solutions.
  • Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet.

Guerbet: Revenue at September 30, 2022

Retrieved on: 
Thursday, October 20, 2022
European Medicines Agency, AMF, GBT, Acceleration, US Foods, Euronext Paris, Research, MRI, Food, AI, Group, CER, Forward-looking statement, Agent handling, MA, Medical imaging, Solution, Security (finance), Pharmaceutical industry, Risk management, Guerbet

Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.

Key Points: 
  • Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.
  • X-Ray revenue at CER decreased by 2.2% at 9 months and 3.1% in Q3 in the wake of the decrease in Optiray sales, while Xenetix sales remained very steady.
  • Against this backdrop, the Group expects 2022 revenue growth to be less than 2% on a like-for-like basis and at constant exchange rates compared with a previously announced range of 2% to 4%.
  • Guerbet (GBT) is listed on Euronext Paris (segment Bmid caps) and generated 732million in revenue in 2021.

Worldwide Angiography Equipment Industry to 2028 - by Device, Procedure, End-users and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Radiology, Health Technology, Health, Adoption, St. Jude Medical, Growth, Abbott Laboratories, Hospital, DRAKON, Research, Guerbet, GE Healthcare, Cardiac catheterization, Fluorescein angiography, Magnetic resonance angiography, Computed tomography angiography, Philips, Digital, Boston Scientific, Medtronic, Medical imaging

The global angiography equipment market is segmented based on the device, procedure, and end-users.

Key Points: 
  • The global angiography equipment market is segmented based on the device, procedure, and end-users.
  • Based on the device, the market is segmented into angiography systems, computed tomography angiography, digital subtraction angiography, magnetic resonance angiography, catheters tube, guide wires, balloons, and others including vascular closure devices and other accessories.
  • Based on the procedure, the market is sub-segmented into coronary angiography, fluorescein angiography, microangiography, neuro-vascular angiography, and peripheral angiography.
  • Geographically the global angiography equipment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.